Today's globalisation has forced pharmaceutical companies to expand their existing markets and continuously search for new markets. There is a growing trend toward mergers and acquisitions within the pharmaceutical industry. This process of consolidation is creating challenges and opportunities for pharmaceutical companies utilising it as a means of gaining entry into foreign markets. This current ‘desire to acquire’ may not always be the most appropriate method by which to enter a foreign market.
This paper will outline the strategic issues, as well as giving insights for pharmaceutical companies wishing to enter foreign markets. This will be achieved via a conceptual framework and model for entry to the international pharmaceutical market. In addition, the paper will discuss the implications of entry into foreign markets and the need for and direction of future research.
ThayerA. M. (1999) ‘Drug producers post increased sales, earnings’, Chemical & Engineering News, 77, 33–34.
7.
WechslerJ. (1999) op. cit..
8.
(1999) ‘Experts predict growing revenue, greater expense in global market’, Medical Marketing and Media, 34, 18.
9.
Medical Marketing and Media.
10.
YuguanW.SongJ. (1999) op. cit..
11.
SteinertB.W. (1998) ‘Harmonisation: International rules coming to a planet near you’, SRA Journal, 30, 69–71.
12.
MilmoS. (1998) ‘ICH seeks common ground’, Chemical Market Reporter, 254, FR19–FR21.
13.
Chemical Market Reporter.
14.
ChaudhryP.DacinP. (1997) ‘Strategic planning in a regulated trade bloc: The pharmaceutical industry in the European Union’, European Management Journal, 15, 686–697.
15.
WechslerJ. (1999) op. cit..
16.
op. cit..
17.
op. cit..
18.
StermanA. B. (1998) ‘Competitive advantage through medical marketing excellence’, Pharmaceutical Executive, 18, 108–120.
19.
YuguanW.SongJ. (1999) op. cit..
20.
op. cit..
21.
PrahaladC.K.LieberthalK. (1998) ‘The end of corporate imperialism’, Harvard Business Review, 76, 69–79.
22.
Harvard Business Review.
23.
YuguanW.SongJ. (1999) op. cit..
24.
op. cit..
25.
WechslerJ. (1999) op. cit..
26.
MilmoS. (1998) op. cit..
27.
WechslerJ. (1999) op. cit..
28.
MilmoS. (1998) op. cit..
29.
GopalK. (1999) op. cit..
30.
YuguanW.SongJ. (1999) op. cit..
31.
WechslerJ. (1999) op. cit..
32.
TorresC. (1999) ‘Argentina IS tricky ground for U.S. drug makers: Lax enforcement of treaty causes a loss of sales’, The Wall Street Journal, 3rd December, A13.
33.
WechslerJ. (1999) op. cit..
34.
PrahaladC.K.LieberthalK. (1998) op. cit..
35.
ShamaA. (1995) ‘Entry stategies of U.S. firms to the newly independent states, Baltic states, and Eastern European countries’, California Management Review, 37, 90–109.
36.
LevyA. (2001) ‘Cross-border mergers: Promises unfulfilled’, Bloomberg Markets, April, 37–46.
37.
SauerP. (1998) ‘Finding the next blockbuster drug’, Chemical Market Reporter, 254, FR3–FR6.
38.
ScottA. (1999) ‘Drug makers consolidate’, Chemical Week, 161, 29.
39.
HeracleousL.MurrayJ. (2001) ‘The urge to merge in the pharmaceutical industry’, European Management Journal, 19, 430–437.
MirasolF. (1999) ‘Pharmaceutical industry sees more mergers and acquisitions’, Chemical Market Reporter, 256, 5, 14.
42.
LangrethR. (1999) ‘Pfizer's Warner bid echoes need for staff,’The Wall Street Journal, 19th November, A3.
43.
JacobsP. (1999) ‘Merger to create new biotech giant; health: Johnson&Johnson - Centocor deal comes as pharmaceutical firms seek growth areas’, The Los Angeles Times, 22nd July, 3.
44.
LangrethR. (1999) op. cit..
45.
MirasolF. (1999) op. cit..
46.
KobersteinW. (1999) ‘Celebration and labor: A new company's birthday’, Pharmaceutical Executive, 19, 44–64.
47.
LouieL. (2001) op. cit..
48.
KobersteinW. (1999) op. cit..
49.
op. cit..
50.
VeitingerK. (1998) ‘Midsized Players—A model for the 21st century’, Pharmaceutical Executive, 18, 86–94.
51.
Pharmaceutical Executive.
52.
ShamaA. (1995) op. cit..
53.
op. cit..
54.
CelestinoM. L. (1999) ‘Pharmaceuticals, medical and biotechnology’, World Trade, 12, 98–102.
55.
World Trade.
56.
Van ArnumP. (1999) ‘Covance and Parexel International terminate proposed merger’, Chemical Market Reporter, 256, 13.
57.
CelestinoM. L. (1999) op. cit..
58.
ShamaA. (1995) op. cit..
59.
TorresC. (1999) op. cit..
60.
ShamaA. (1995) op. cit..
61.
ThompsonA. (1999) ‘Biotech merger boosts IBT’, European Venture Capital Journal, 1st August, 10–11.
62.
LouieL. (2001) op. cit..
63.
op. cit..
64.
GopalK. (1997) ‘Global branding—Fancy or fact’, Pharmaceutical Executive, 17, 34–36.
65.
HarrisG. (1999) ‘Glaxo Wellcome eyes big market in stomach pain’, The Wall Street Journal, 16th November, B1, B4.
66.
DeSimoneG. (1998) ‘Overcoming obstacles to global branding’, Medical Marketing and Media, 33, 88–95.
67.
SaldanhaG.PesanelloP.HarringtonE. (1997) ‘Building value through global branding’, Pharmaceutical Executive, 17, 72–80.
68.
ChaudhryP.DacinP. (1997) op. cit..
69.
BarrettA.LickingE.CareyJ.CapellK. (1999) ‘Addicted to mergers: Deal making may not be the right prescription for drugmakers’, Business Week, 6th December, 84–90.
